100
100 (ワンダブルオー) is a Kyoto-based femtech startup operating the NCT platform for pain-free breast cancer screening at non-medical venues, serving Japanese women 30s–60s, corporate wellness programs, and local governments via test kits, seminars, and FEMTECH& events.
- Company typePrivate
- Founded2023
- HeadquartersKyoto, Japan
- Headcount—
- GTM typeB2B and B2C
- OfferingServices
What 100 does
株式会社100 (ワンダブルオー / 100 Inc.) is a Kyoto-based femtech startup founded in March 2023 by Hiroko Yamagami, a former pharmaceutical MR and corporate planning executive, to address Japan's low breast cancer screening rate (47.4%, the lowest among OECD countries). The company's core product is NCT (New generation Cancer Test), a pain-free breast cancer screening platform that uses prone-position ultrasound imaging and is positioned for deployment at non-medical venues such as cafes, shopping malls, parks, and corporate offices. The business model is protected by Japanese business model patent No. 7289422, granted June 2023, covering the non-medical-facility testing concept with aftercare support.
NCT is currently pre-commercial at scale; the company monetizes through a hybrid stack: (1) direct-to-consumer test kits and home mineral-balance kits sold via its BASE online shop, (2) B2B corporate wellness seminars and breast cancer awareness events priced per event (named clients include Taiju Life Insurance, Mizkan Holdings, Kadoriru Nishida, Daiwa Lease), and (3) the FEMTECH& sub-brand event platform co-hosted with Wacal Lab and partners such as Madame FIGARO and Mellow., targeting women aged 30s–60s, corporate HR departments, and local governments. Distribution channels span regional pop-ups (Welpa at Shinsaibashi PARCO, AEON Mall Wakayama), the BASE e-commerce storefront, and corporate direct sales.
The company's operating footprint is currently Japan-focused (Kansai home base plus Kanto/Kansai pop-ups, with online nationwide reach), supported by government validation through Kyoto City Startup Social Challenge, Kyoto Prefecture Female Empowerment Program, and Next Innovator. Registered capital is 1M JPY (~$6,700), and the only known external funding is a 2023 CAMPFIRE crowdfunding campaign targeting 10M JPY. No institutional venture funding, revenue figures, or headcount are disclosed.
100 firmographics
Firmographics- Name
- 100
- Legal name
- 株式会社 100（100 Inc.）
- Website
- https://100onewo.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Short description
- 100 (ワンダブルオー) is a Kyoto-based femtech startup operating the NCT platform for pain-free breast cancer screening at non-medical venues, serving Japanese women 30s–60s, corporate wellness programs, and local governments via test kits, seminars, and FEMTECH& events.
- Ownership category
- akta.pro rank
100 industry classification
Industry- Product category
- Women's Health Screening Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)
- akta.pro secondary industries
- Home-Use & OTC Rapid Self-Tests (Consumer POCT kits) (HLAHAOAK), Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK), Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)
Keywords
Where 100 is headquartered
LocationHeadquarters
- HQ city
- Kyoto
- HQ country
- Japan
- HQ region
- Asia
Offices1 record
Markets served
100 business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Marketing or Sales, Operations, Technology or R&D, Others
Revenue model
- Product Sales: Sale of breast cancer risk test kits, mineral test kits, and other health screening products through BASE online shop and pop-up stores.
- Event Planning and Consulting Services: Corporate wellness seminars, breast cancer awareness seminars for companies, event planning and management for Femtech events.
- NCT Service Platform: Next-generation cancer testing services offered at non-medical facilities, with appointment booking through smartphone and results delivery via mobile app.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Product sales with variable pricing |
| Other | Multi-year contract | Corporate seminar and event services |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels5 records
100 product offering
Product offeringCore offering
株式会社100 (100 Inc.) operates the NCT (New generation Cancer Test) platform, a next-generation cancer testing service that delivers pain-free breast cancer screening at non-medical locations such as cafes, shopping malls, and parks using ultrasound and other non-invasive modalities. The company also sells home-use test kits (breast cancer risk and mineral balance) through its BASE online shop, runs corporate breast cancer awareness seminars for enterprise clients, and curates the FEMTECH& branded event series to drive women's health awareness.
Product overview
株式会社100 (100 Inc.) operates as a healthcare/femtech startup offering NCT (New generation Cancer Test) - a next-generation cancer testing platform. The core offering includes pain-free breast cancer screening services using innovative technology (prone-position ultrasound) available outside medical institutions at accessible locations. The company also sells home-use testing kits (breast cancer risk and mineral balance), operates the FEMTECH＆ sub-brand for femtech events and projects, and provides well-being consulting services. The product portfolio centers on democratizing cancer screening through the NCT platform while expanding reach via the FEMTECH＆ concept brand and supporting health-related events and seminars.
Differentiator
Problem solved
Functional benefit
Products and services
- NCT (New generation Cancer Test) Cancer Screening Service Pain-free breast cancer screening service using ultrasound imaging in prone position and other non-invasive modalities, delivered at cafes, shopping malls, and other daily-accessible non-medical locations with 30-minute testing and smartphone booking/results. Targets women who delay or avoid traditional mammography due to pain, embarrassment, time constraints, or facility access issues.
- NCT Home-use Test Kits (Breast Cancer Risk & Mineral Balance) Direct-to-consumer test kits for at-home breast cancer risk assessment and mineral balance measurement, providing women with convenient, accessible health screening options outside clinical settings.
- Corporate Wellness Seminars (B2B) B2B breast cancer awareness seminars, Pink Ribbon Month initiatives, and employee wellness programs delivered to corporate HR departments and management, targeting female employees and addressing low screening rates in Japan's workforce.
- Well-being Consulting & Event Planning Services Planning, sales, and consulting services for well-being and Femtech initiatives, including event planning and management, Femtech event production, and health promotion program consulting for corporations and communities.
Quantifiable outcome
- 日本的乳がん検査受診率は47.4%にとどまり、OECD加盟国中最下位
- +2 more outcomes
Companies that use 100
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
100 technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
100 partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered minor, major, strategic and core.
- フィガロジャボン Business with Attitude (BWA)minorMedia partner for 3rd anniversary FEMTECH& WAKEWAKE Project event. Women's entrepreneurship media platform partnership.
- 大樹生命株式会社 (Taiju Life Insurance)minorBreast cancer screening seminar at Taiju Life Kyoto sales office. Corporate wellness initiative for insurance company employees.
- 大和リース株式会社 (Daiwa Lease)majorDemonstration project partner for adding wellness value to parks. Co-hosted events at Omiya Traffic Park in Kyoto testing park as new health infrastructure. Partnered for Pink Ribbon Month breast cancer awareness seminar.
- 京都府 (Kyoto Prefecture)majorGovernment backer for female health events. Supported 年はじめ Petit Tea Event for Women's Health as co-host. Backed by prefecture for women's empowerment initiatives.
- 心斎橋PARCO / Welpa (Welpa Medical Wellness Mall)majorPop-up store host for FEMTECH& event at Shinsaibashi PARCO 10F medical wellness area. December 2024 - January 2025 retail and event partnership.
- Mellow. (メロウドット)strategicCollaboration brand for FEMTECH& diversity-themed pop-up store at PARCO. Genderless intimate zone skincare brand partnership for the event.
- 株式会社ミズカン Holdings (Mizkan Holdings)minorOnline seminar speaker for Mizkan Group employees on entrepreneurship and career transformation. Employee engagement initiative.
- 一般社团法人ワーカルラボ (Wacal Lab)coreCo-host organization for FEMTECH& project. Jointly organized first major project: わかる！助かる！フェムテック展in 和歌山市 at AEON Mall Wakayama with 500+ visitors. Continued partnership for Local Woman's Health Lab Symposium in Kyoto.
- 合同会社五方よし (Go-Ho-Yoshi LLC)coreMOU (basic agreement) signed for cooperation in NCT concept social implementation. Partnership focuses on cancer screening democratization and joint event planning/support. Five-point partnership aimed at improving cancer screening accessibility.
Scale indicators4 records
Recent moves6 records
Expansion highlights12 records
100 competitors and assessment
Company assessmentBroad incumbents
- iCAD: Provider of AI-based breast cancer detection and risk-stratification software used alongside mammography — adjacent technology player competing for the same screening-quality and early-detection value proposition.
- Philips: Global medtech incumbent with breast imaging (ultrasound, mammography) and patient monitoring portfolio — provides the established, well-capitalized alternative that any non-clinical breast screening entrant must defend against.
- Volpara Health Technologies: Software-focused breast cancer screening analytics and risk-assessment vendor — comparable analytics/digital-health layer that overlaps with NCT's aspiration to deliver quantitative, accessible breast cancer risk insight.
- Hologic: Global leader in mammography and breast cancer diagnostics (Genius 3D Mammography, Brevera). Broad incumbent in breast cancer screening that any non-mammography entrant like NCT must position against.
- GE HealthCare: Major incumbent in breast imaging (ultrasound, mammography, contrast-enhanced mammography) — comparable adjacent modality (ultrasound) used by NCT and the same target use case (breast cancer screening).
Direct peers
- Braster: Poland-based company behind Braster Pro, a contact breast cancer screening device for at-home and non-clinical use — closely aligned pain-free, non-mammography breast screening concept targeting women who skip conventional screening.
- UE LifeSciences: US/India-based company offering 'iBreastExam' and similar no-touch breast scanning devices deployed in pharmacies and non-clinical settings — direct analogue of NCT's non-medical-facility breast cancer screening distribution thesis.
- Lily MedTech: Japanese startup developing a ring-shaped ultrasound device for breast cancer screening — same Japan-based mission of replacing painful mammography with more accessible, patient-friendly screening technology.
- Pickles (ピクルス): Japanese femtech startup offering at-home cervical cancer self-screening test kits — comparable direct-to-consumer, at-home/outside-hospital cancer screening model targeting Japanese women who avoid conventional screening.
Emerging players
- Niramai Health Analytix: India-based startup offering non-touch, privacy-aware breast cancer screening deployable in non-clinical settings — emerging-market analogue pursuing the same 'screening outside the hospital' thesis as NCT.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
100 social profiles
Digital presence100 financial estimates
Financial estimateRevenue estimate
Valuation estimate
100 leadership team
Management profileNumber of profiles
Profiles3 records
100 funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
100 M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 100
What does 100 do?
株式会社100 (100 Inc.) operates the NCT (New generation Cancer Test) platform, a next-generation cancer testing service that delivers pain-free breast cancer screening at non-medical locations such as cafes, shopping malls, and parks using ultrasound and other non-invasive modalities. The company also sells home-use test kits (breast cancer risk and mineral balance) through its BASE online shop, runs corporate breast cancer awareness seminars for enterprise clients, and curates the FEMTECH& branded event series to drive women's health awareness.
Is 100 a public or private company?
100 is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was 100 founded?
100 was founded in 2023.
Where is 100 based?
100 is headquartered in Kyoto, Japan, in the Asia region.
How does 100 make money?
Three revenue lines are on record. Product Sales are the primary driver. The others are event Planning and Consulting Services and NCT Service Platform.
Who are 100's main competitors?
Broad incumbents on record are iCAD, Philips, Volpara Health Technologies, Hologic and GE HealthCare. Direct peers are Braster, UE LifeSciences, Lily MedTech and Pickles (ピクルス). Niramai Health Analytix is listed as an emerging player.
Does 100 have an API?
No public API is recorded for 100.
What industry is 100 in?
100's product category is Women's Health Screening Services. Its primary akta.pro industry code is HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers), with a secondary code of HLAHAOAK, Home-Use & OTC Rapid Self-Tests (Consumer POCT kits). Its NAICS code is 621511 and its SIC code is 2835.